Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Inqovi combines decitabine, a hypomethylating agent, with cedazuridine, a cytidine deaminase inhibitor that allows decitabine to be taken orally instead of by injection, offering a more convenient alternative to IV hypomethylating therapy.
Inqovi is FDA-approved for adult patients with myelodysplastic syndromes (MDS), including chronic myelomonocytic leukemia (CMML), across intermediate and high-risk IPSS categories. It is also approved, in combination with venetoclax, for newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or with comorbidities that preclude intensive induction chemotherapy.
Decitabine incorporates into DNA and inhibits DNA methyltransferase, reactivating tumor suppressor genes silenced by abnormal methylation. Cedazuridine inhibits the enzyme that would otherwise rapidly break down oral decitabine, allowing effective oral dosing.
The recommended dose is one tablet (35 mg decitabine / 100 mg cedazuridine) taken orally once daily on Days 1 through 5 of each 28-day cycle, on an empty stomach, as determined by the treating hematologist-oncologist.
Inqovi requires close monitoring for several important safety considerations.
Severe myelosuppression, including fatal adverse reactions, can occur. Obtain complete blood counts before starting treatment, before each cycle, and as clinically indicated to monitor for response and toxicity.
Increased risk of serious infections due to myelosuppression. Monitor for signs of infection throughout treatment.
Inqovi can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Inqovi (decitabine and cedazuridine) is manufactured by Taiho Oncology, offering an oral alternative to injectable hypomethylating agents for MDS, CMML, and AML.
Import of Inqovi through a Named Patient Program requires a valid prescription from the treating hematologist-oncologist, confirmation of diagnosis and risk category, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Inqovi directly from Taiho Oncology's authorized supply chain to ensure product authenticity and regulatory compliance.
Inqovi is sourced through verified, GDP-compliant channels from Taiho Oncology's authorized supply chain to ensure authenticity and quality.
Inqovi tablets should be stored at 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F), in original packaging.
Once sourced, Inqovi is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Inqovi through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hematology-oncology centers in Mumbai support MDS/AML diagnosis and treatment coordination for Inqovi access.
Delhi's major cancer hospitals assist patients with diagnostic confirmation and prescription support for Inqovi.
Bangalore's oncology network offers access to MDS/AML treatment planning for eligible patients.
Chennai-based specialists coordinate Inqovi access alongside comprehensive hematologic malignancy care.
Hyderabad's cancer care institutions support patients pursuing Inqovi therapy.
Kolkata's oncology centers help coordinate documentation and treatment access for Inqovi.
Pune-based hematologists assist with diagnosis confirmation and Inqovi treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Inqovi.
Kochi's oncology units assist patients with the documentation needed for Inqovi access.
Chandigarh's cancer care centers support Inqovi treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Inqovi access process.
Lucknow-based cancer centers assist patients pursuing Inqovi therapy.
Bhubaneswar's oncology institutions support access to Inqovi for eligible patients.
Guwahati's specialists help coordinate Inqovi access for patients across the Northeast.
Patients in other cities across India can also access Inqovi through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
